Home » Topics » BioWorld Science

BioWorld Science
RSS

Nicotinamide riboside shows promise for myocardial infarction

Sep. 10, 2019

Passage Bio licenses gene therapy program for CMT2A from Penn

Sep. 9, 2019

Acadia's phase III study of pimavanserin in dementia-related psychosis meets primary endpoint

Sep. 9, 2019

Theravance reports first-in-human data on TD-8236 for inflammatory lung disease

Sep. 9, 2019

Bristol-Myers Squibb designs RORgammaT inverse agonists showing biologic-like efficacy

Sep. 9, 2019

AstraZeneca reports phase III data on Imfinzi in previously untreated extensive-stage SCLC

Sep. 9, 2019

Vicore completes phase I study of angiotensin II type 2 receptor agonist C-21

Sep. 9, 2019

Boehringer Ingelheim, Hydra Biosciences patent TRPC6 antagonists

Sep. 9, 2019

AstraZeneca presents arginase-1 and arginase-2 inhibitors

Sep. 9, 2019

New PD-1/PD-L1 interaction inhibitors described by Gilead Sciences

Sep. 9, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...